RxDoctor Payments Data

Vineet Korrapati, MD

Gastroenterology · Salisbury, NCNPI 1003196353

Payments from drug & device makers

$44,935in general payments, 2019–2025

Across 946 payments — averaging $47.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • Ironwood Pharmaceuticals, Inc$6K
  • Adare Pharmaceuticals, Inc.$3K
  • Gilead$2K
  • Redhill Biopharma Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $10K from 40 others

What the payments were for

  • Consulting fees$1,3203%
  • Speaking & faculty fees$20,97550%
  • Travel & lodging$5311%
  • Food & beverage$18,91145%
  • Education$1440%
  • Gifts$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,935 in reported general payments places this provider in the 85th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$202,844
Medicare patients
364
Services billed
3,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$144,049
LinzessLinaclotide116$142,662
ZenpepLipase/Protease/Amylase32$121,387
Infliximab12$48,632
CreonLipase/Protease/Amylase23$43,215
IbsrelaTenapanor Hcl11$34,692
MovantikNaloxegol Oxalate32$20,808
Dexlansoprazole DrDexlansoprazole19$5,782
Omeprazole304$4,216
Pantoprazole Sodium540$3,951
TrulancePlecanatide13$3,847
Sucralfate22$1,971
Famotidine124$1,626
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl86$1,330
Esomeprazole Magnesium20$1,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$20,793$185,877139 claims
Aimmune Therapeutics, Inc.Zenpep$168$121,38732 claims
Ardelyx, Inc.Ibsrela$599$34,69211 claims
Redhill Biopharma Inc.Movantik$1,697$20,80832 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,439$3,84713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →